Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: Implication for intermittent imatinib therapy

Leukemia and Lymphoma

Volumn 50, Issue 6, 2009, Pages 944-951

  Goh, Hyun Gyung ^a   Kim, Yoo Jin ^a   Kim, Dong Wook ^a   Kim, Hyeoung Joon ^b   Kim, Soo Hyun ^a   Jang, Se Eun ^a   Lee, Jeong ^a   Kim, Dongho ^a   Kim, Wan Seok ^a   Park, Sa Hee ^a   Kweon, Il Young ^a  

^a The Catholic University of Korea   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Chronic myeloid leukemia; Complete cytogenetic response; Complete molecular response; Intermittent imatinib therapy

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DOSE RESPONSE; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68449094991     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902926973     Document Type: Article

References (16)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:130-134.
2. Talpaz M, Silver RT, Druker BJ, Goldman JM. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002;99:1928-1937.
3. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375-2384.
4. Deininger M, Goldman J, Melo J. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-3356.
5. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 1996;2:561-566.
6. O'Brien SG, Francois G, Larson RA, Insa G, Michele B, Francisco C. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
7. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon. Blood 2004;104:1979-1988.
8. Cortes J, O'Brien S, Kantarjian HM. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004;104:2204-2205.
9. Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lassarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005;90:979-981.
10. Breccia M, Diverio D, Pane F, Nanni M, Russo E, Biondo F, et al. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph+CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. Leuk Res 2006;30:1577-1579.
11. Micheal JM, Brian JD, Richard TM. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004;28:71-73.
12. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2006;109:58-60.
13. Verma D, Kantarjian H, Jain N, Cortes J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon a. Leuk Lymphoma 2008;49:1399-1402.
14. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007;110:2828-2837.
15. Hochhaus A, Druker BJ, Larson RA, O'Brien SG, Gathmann I, Guilhot F. IRIS 6-Yeay follow-up: Sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib. Blood 2007;110:15a-16a; Abstract 25.
16. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-325.